Literature DB >> 7379053

Tamoxifen in metastatic malignant melanoma.

F L Meyskens, J B Voakes.   

Abstract

Eight patients with advanced metastatic malignant melanoma were treated with tamoxifen at a dose of 10 mg orally twice a day for a minimum of 4 weeks. There was one complete response of skin disease occurring over a period of 40 weeks. This patient has remained disease-free for 8+ weeks. Two other patients demonstrated a partial but brief (4 weeks) shrinkage of gross subcutaneous disease. Three patients exhibited no response to the drug, but two patients had rapid acceleration of disease between the second and fourth weeks of treatment. Further exploration of the basis for these favorable and adverse responses is being pursued.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7379053

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  3 in total

1.  Sex differences in the association of cutaneous melanoma incidence rates and geographic ultraviolet light exposure.

Authors:  Feng Liu-Smith; Ahmed Majid Farhat; Anthony Arce; Argyrios Ziogas; Thomas Taylor; Zi Wang; Vandy Yourk; Jing Liu; Jun Wu; Archana J McEligot; Hoda Anton-Culver; Frank L Meyskens
Journal:  J Am Acad Dermatol       Date:  2016-10-26       Impact factor: 11.527

2.  Steroid hormone receptors in human melanoma.

Authors:  H J Grill; P Benes; B Manz; P Schramm; B Morsches; G W Korting; K Pollow
Journal:  Arch Dermatol Res       Date:  1982       Impact factor: 3.017

3.  Topical toremifene: a new approach for cutaneous melanoma?

Authors:  J Maenpaa; T Dooley; G Wurz; J VandeBerg; E Robinson; V Emshoff; P Sipila; V Wiebe; C Day; M DeGregorio
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.